FDA-Approved Ketamine Spray Outperforms Prozac, Patients Say

Patients Say an FDA-Approved Ketamine Treatment Beat Years on Prozac

A New York Post report published October 15, 2026 features patients who say an FDA-approved ketamine-based treatment relieved their depression faster and more completely than years spent on fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI) first approved by the FDA in 1987. The outlet's description identifies this as patient testimony rather than a clinical trial result, and the specific drug isn't named in the available summary, but the details point to esketamine, sold under the brand name Spravato, the only ketamine-derived nasal spray the FDA has approved for depression.

Esketamine received FDA approval in 2019 for treatment-resistant depression (TRD), defined as depression that hasn't responded to at least two prior antidepressants, and again in 2020 for major depressive disorder with acute suicidal ideation. Spravato is approved for use alongside, not instead of, an oral antidepressant. That detail matters here: patients describing it as outperforming "decades on Prozac" are likely describing an add-on treatment, not a head-to-head swap.

Why Esketamine Isn't the Same as Low-Dose Ketamine Infusions

Readers of this site should note a distinction the Post article doesn't need to make but we do: esketamine (Spravato) is one of two mirror-image molecules in racemic ketamine, delivered as a nasal spray in a certified clinic under a Risk Evaluation and Mitigation Strategy (REMS) program required by the FDA. Patients must be monitored for at least two hours after each dose and cannot drive themselves home the same day. Low-dose ketamine infusions, lozenges, and intramuscular injections, the formats more commonly discussed on this site, use the full racemic molecule and remain off-label for depression. They are administered at the prescriber's discretion rather than under an FDA-mandated monitoring protocol, which means the safety infrastructure, dosing standards, and insurance coverage differ meaningfully from Spravato.

Both approaches share a proposed mechanism: rapid modulation of NMDA receptors and downstream effects on glutamate signaling, which researchers believe produces faster mood changes than the weeks-long onset typical of SSRIs like Prozac. That shared mechanism is likely why patients across both esketamine and low-dose ketamine protocols report similar themes, speed of relief and effectiveness after SSRIs failed, even though the products, dosing, and regulatory oversight aren't interchangeable.

What the Evidence Actually Supports in 2026

According to the FDA's 2019 approval record, esketamine's pivotal trials measured symptom reduction over four weeks in adults with treatment-resistant depression, a population that had already failed multiple antidepressants, not a general comparison against Prozac in average patients. That's an important scope limit: "better than decades on Prozac" as a patient's lived experience is a meaningfully different claim than "superior in controlled trials to SSRIs broadly," and the available reporting supports only the former.

What is well established is that treatment-resistant depression is common. Estimates commonly cited in psychiatric literature suggest roughly one-third of patients with major depressive disorder don't achieve adequate response after two or more antidepressant trials, which is the exact population esketamine was designed for. For patients in that group, a faster-acting, structurally different option is clinically significant even without claims of broad superiority over SSRIs.

Practical Takeaways for Readers Weighing Ketamine-Based Options

If you're reading patient accounts like the ones in the Post and wondering whether a ketamine-based treatment fits your situation, a few questions are worth asking before scheduling anything in 2026. First, has your current antidepressant actually failed, meaning an adequate dose for an adequate duration (typically six to eight weeks), or would adjusting the current medication be worth trying first? Second, ask whether you're being offered esketamine (Spravato), with its REMS monitoring requirement, or an off-label racemic ketamine protocol, since the oversight, cost structure, and dosing schedule differ. Third, confirm how maintenance dosing is planned; both esketamine and low-dose ketamine typically require ongoing sessions (often tapering from twice weekly to monthly) to sustain benefit, and relapse after stopping treatment is common if maintenance isn't addressed upfront.

Finally, don't discontinue an existing antidepressant on your own based on anecdotal reports. Any transition should be managed by a prescriber who can monitor for withdrawal effects from the SSRI and assess whether you meet the clinical criteria, treatment-resistant depression or acute suicidal ideation, that the FDA's approval for esketamine actually covers. The original reporting is available via the New York Post.